Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for ...
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a ...
The list of recalled food products being elevated to Class I (the highest recall level) by the U.S. Food and Drug Administration (FDA) is continuing to grow. This time, the organization has updated ...
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, known as suzetrigine, is the first new painkiller approved in the U.S. since 1998. It can be used to relieve pain after surgery or injury, and some researchers say it might be the start of a ...
What will the industry face or achieve in 2025? These trends will be critical in medical device cybersecurity.
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...